Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related ...